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ABSTRAK
Chronic thromboembolic pulmonary hypertension (CTEPH) saat ini masih mengalami underdiagnosis 
dan sebagai konsekuensinya juga undertreatment dalam praktik klinis. Kurangnya modalitas diagnosis dan 
ketersediaan modalitas tata laksana terutama di negara berkembang membuat diagnosis CTEPH sulit ditegakkan. 
Namun dengan indeks kecurigaan klinis terhadap CTEPH yang tinggi akan menuju ke diagnosis yang tepat 
dan terapi yang benar sehingga dapat menurunkan angka kesakitan dan kematian. Bila tidak diterapi, angka 
kesintasan rerata 6,8 tahun dan angka kematian dalam tiga tahun dapat mencapai 90%. Patofisiologi, diagnosis 
dan tatalaksana CTEPH perlu untuk diperkenalkan  kepada para internis dan dokter pelayanan primer, sehingga 
outcome pasien dapat lebih baik.
Kata kunci: chronic thromboembolic pulmonary hypertension, diagnosis, hipertensi pulmoner.
ABSTRACT
Chronic thromboembolic pulmonary hypertension (CTEPH) is currently underdiagnosis and consequently 
undertreatment in the clinical practice. A deficient in diagnostic modality and treatment availability especially in 
developing countries makes the CTEPH diagnosis unlikely to confirm. However, high index of clinical suspicion 
of CTEPH will lead to proper diagnosis and correct treatment  with significant reduction in morbidity and 
mortality. Left untreated, the mean survival time is 6.8 years and the three year mortality rate may be as high 
as 90 %. The pathophysiology, diagnosis and treatment of CTEPH are necessary to be shared among internists 
and primary care physicians, in order to improve the overall outcome of the patients.
Keywords: chronic thromboembolic pulmonary hypertension, diagnosis, pulmonary hypertension.
INTRODUCTION
Pulmonary hypertension is defined as an 
elevated mean pulmonary arterial pressure 
(mPAP) ≥25 mmHg in resting condition measured 
by invasive right heart catheterisation.1 Current 
grouping of pulmonary hypertension have 
classified five groups of this disease, as follows: 
(1) Group 1 is pulmonary arterial hypertension, 
(2) Group 2 is pulmonary hypertension due to 
left heart disesase, (3) Group 3 is pulmonary 
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hypertension due to lung disease and/or 
hypoxia, (4) Group 4 is chronic thromboembolic 
pulmonary hypertension (CTEPH) and other 
pulmonary artery obstruction, and  (5) Group 5 is 
pulmonary hypertension with unclear mechanism 
and/or multifactorial origin.1 As a clinical entity, 
however, CTEPH is currently underdiagnosis 
and consequently undertreatment. This fact 
may be due to lack of diagnosis modality and 
treatment availability especially in developing 
countries.
The prevalence of CTEPH is 3.2 cases per 
million person and the incidence is 0.9 cases per 
million person. Most CTEPH cases are preceded 
by episode of acute pulmonary embolism (75%) 
and deep veins thrombosis (56%), indicating that 
CTEPH is persistent thromboembolic state.2 The 
incidence of CTEPH after an episode of acute 
pulmonary embolism varies between 0.1% and 
9.2%.2 This large range of reported CTEPH 
incidence following acute pulmonary embolism 
reflects the referral bias, difficulty in early 
diagnosis from several hospitals and variation 
of standardised diagnostic method.2 However, a 
quarter of CTEPH patients does not experience 
previous acute pulmonary embolism and there is 
no direct association between acute pulmonary 
embolism with CTEPH.2 Left untreated, the 
mean survival time is 6.8 years and in CTEPH 
patients with mean pulmonary artery pressure 
(mPAP) >50 mmHg the three year mortality 
rate is 90%.3
To lead the diagnosis of CTEPH, the high 
index of clinical suspicion is required and 
followed by several diagnostic modalities. The 
risk factors of CTEPH have been identified to aid 
the direction of diagnosis. The risk factors are 
splenectomy, indwelling catheters, indwelling 
pacemaker leads, infected ventriculoatrial shunts, 
levothyroxin treatment, malignancy, chronic 
inflammation condition such as osteomyelitis, 
inflammatory bowel diseases, systemic lupus 
erithematosus and antiphospolipid syndrome, 
and staphylococcal infection.2 Since several 
treatment options are currently available and 
evolving significantly, internists and primary care 
physicians need to be familiarised with CTEPH 
in order to improve the overall outcome of the 
patients. This review intends to introduce the 
pathophysiology, the challenge in diagnostic 
modality and the current treatment strategy for 
CTEPH.
CTEPH – THE PATHOPHYSIOLOGY
The main pathology finding in CTEPH is 
an occlusive pulmonary arterial remodeling as a 
consequence of persistent thromboembolism in 
major pulmonary arteries.1 In the affected artery, 
usually the elastic type pulmonary arteries such 
as major artery, lobar artery, segmental artery and 
subsegmental artery, organized chronic thrombi 
or emboli obstruct the blood flow which cause 
reduced distal perfusion.1 The term chronic 
means that the obstruction takes place more than 
three months even after effective anticoagulation 
strategy.
The exact mechanism of the genesis of 
CTEPH is currently not fully understood. The 
reproduction of CTEPH in experimental cellular 
and animal model has been proven difficult, 
therefore hindering the elucidation of basic 
molecular mechanism behind CTEPH. In human 
study, the fibrotic transformation from pulmonary 
artery thrombus is a hallmark of CTEPH.2,3 The 
intraluminal fibrotic tissue obstructs pulmonary 
artery blood flow. Abnormal trombus resolution 
and subsequent vascular remodeling with 
occlusive fibrotic transformation is currently 
suggested as an explained pathogenesis of 
CTEPH.4 The schematic represantation of the 
pathophysiology of CTEPH is depicted in 
Figure 1.
In most cases, thrombi will disappear from 
blood circulation through haemostatic processess 
which includes thrombus degradation and 
organisation. During resolution of thrombi, 
leucocyte recruitment and angiogenesis have 
an important role.4 In early phase, neutrophils 
and monocytes were recruited in the ongoing 
organised thrombi, in which monocytes express 
and secret chemoattractant mediator.4 Several 
inflammatory markers are increased in plasma 
and thrombotic tissue in CTEPH, such as 
C-reactive protein (CRP), tumour necrosis 
factor-alpha  and MCP-1.4,5 The receptor of 
CRP, i.e. LOX-1 is highly expressed in the cells 
isolated from CTEPH specimens indicating the 
inflammatory thrombosis is prevailing in the 
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pathogenesis of CTEPH.4,5 Host immunology 
and genetic susceptibility are thought to be 
the predisposing factor to develop persistent 
occlusive thrombus.4
Surgery specimen shows that CTEPH lesion 
is similar to atherosclerotic lesion.5 There are two 
types of intimal lesion from the surgery specimen, 
as follows: (1) fibrous plaque with angiogenesis 
and (2) atherosclerotic plaque composed of 
cholesterol, macrophage, T lymphocyte and 
calcium.5 Pathologic examination reveals several 
grades of thrombi remodeling and organisation 
with degrees of inflammation and types of cells 
mixed with organised and thickened intima in 
which scattered by collagen, calcification and 
atherosclerosis.5,6 Figure 2 shows an example of 
CTEPH specimen of pulmonary artery.
Angiogenesis in CTEPH depends on vasa 
vasorum originates from systemic circulation 
of bronchial artery. The collateral of bronchial 
artery is opened in response to occlusion 
in pulmonary artery. Positive angiogenesis 
regulator is increased during thrombus 
organisation processess. Activated endothelial 
cells migrate and penetrate occlusive thrombus 
starting recanalisation and remodeling.4 In 
addition to major pulmonary artery, small 
distal pulmonary vessel may undergo similar 
remodeling which contribute to the pathogenesis 
of CTEPH. Clinical facts support the suggestive 
pathogenesis, as follows: (1) lack of association 
between increased pulmonary artery pressure 
and obstruction of pulmonary vascular examined 
by angiography, (2) progression of pulmonary 
hypertension despite absence of recurrent 
emboli, (3) persistent high pulmonary vascular 
resistance in CTEPH if compared with acute 
pulmonary embolism with similar degree of 
vascular obstruction.5
Vascular lesion in CTEPH involves two 
vascular components, i.e. major artery or 
macrovascular and small artery or microvascular.4 
Organised thrombus which strongly attach 
to the medial layer of elastic type pulmonary 
artery is the main pathology in macrovascular 
lesion. These thrombus are scattered, replace 
normal intimal layer and express excessive 
plasminogen activator inhibitor type 1 (PAI-1) 
which hinder fibrinolysis activity of adjacent 
normal endothelial cells.4 Collateral vessels from 
broncial artery vascularise the area originally 
nurture by obstructed vessel and therefore, 
maintain the organised thrombus.2 Microvascular 
lesion includes distal muscularisation, concentric 
fibroelastosis in intimal layer, eccentric intimal 
fibrosis, medial hyperthrophy and plexyform 
lesion.2,4 These arteriopathies are due to 
sequelae of endothelial dysfunction, abnormal 






















Figure 1. Schematic representation of pathogenesis of 
CTEPH4
Figure 2. The pathologic appearance of organized 
thrombi in CTEPH of the pulmonary artery, showing the 
luminal narrowing alongside with organized thrombi. The 
thrombi contained fibrous intimal hyperplasia scattered by 
recanalized channels (Taken from: Ogawa and Matsubara, 
201523 with permission)
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and endothels, fibroblastic migration, smooth 
muscle cell migration,  reduced smooth muscle 
cells apoptosis and in situ thrombosis.4
There are four type of CTEPH pathologies 
according to Jamieson classification, i.e. type I 
is thrombus in major vessels and clearly seen 
in the major pulmonary artery, it constitute 
12% of cases, type II is no thrombus in major 
vessels, there is intimal thickening with webs in 
bifurcations of lobar arteries, it constitute 38% 
cases, type III is thrombus and vascular lesion 
in distal vessels and localised in segmental and 
subsegmental branches, it constitutes 39.3% 
cases and type IV is no proven thromboembolic 
material despite surgery exploration and 
intimectomy.2
CTEPH – THE DIAGNOSIS
Guideline in Diagnostic Flow
In the early stage of disease, the signs and 
symptoms are not specific or even undetected. 
In the later stage, the signs of right heart 
failure are clearly seen. The clinical picture 
of CTEPH is in somedegree similar to acute 
pulmonary embolism or  idiophatic pulmonary 
artery hypertension.1 High index of suspicion is 
necessary to lead for working up the diagnosis 
of CTEPH. To diagnose CTEPH, the signs and 
symptoms should be existed after 3 months 
following the effective anticoagulants in order 
to differentiate with subacute pulmonary 
embolism.1 Around 75% CTEPH patients have 
previous history of acute pulmonary embolism 
and 56% have previous deep vein thrombosis.7
The guideline of European Society of 
Cardiology (ESC) published in 2015 provides 
an algorithm to diagnose CTEPH. The presence 
of pulmonary hypertension is detected firstly by 
non invasive transthoracal echocardiography. 
Moderate to high probability of pulmonary 
hypertension from echocardiogram prompts 
further diagnostic follow up. The ventilation/
perfusion lung scan (V/Q scan) is the firstline 
imaging modality to diagnose CTEPH. It gives 
96-97% sensitivity and 90-97% specificity.1 
Multidetector CT pulmonary angiography 
(MDCTPA) is next imaging modality to confirm 
the diagnosis of CTEPH after V/Q scan. Both 
V/Q scan and MDCT pulmonary angiography 
have high sensitivity, specificity and accuracy to 
detect and diagnose CTEPH. Invasive procedure, 
such as right heart catheterisation and/or selective 
pulmonary artery angiography, is recommended 
for the final diagnostic step (Figure 3).1


















right heart catheterisation +/-
pulmonary angiography
Figure 3. Diagnosis flow of CTEPH based on European 
Society of Cardiology guideline 20151
Routine Examination
Routine examination such as chest X-ray in 
the early disease is normal. In the progressing 
disease, the signs of pulmonary hypertension 
can be detected in chest X-ray, i.e. major 
pulmonary artery dilatation, cardiomegaly and 
oligemia. Lung function test may be useful to 
exclude primary lung disease which may be an 
underlying cause of pulmonary hypertension. 
Laboratory examination does not have value to 
diagnosis CTEPH. Electrocardiogram supports 
the presence of pulmonary hypertension although 
its sensitivity and specificity is not adequate 
(55% and 70%, respectively). Most CTEPH 
patients have electrocardiogram patterns of right 
axis deviation (50%) and negative T wave in 
V1-V4 precordial leads (62%).8
Echocardiography
Transthoracal echocardiography examination 
is the first step to diagnose pulmonary hypertension. 
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It estimates the pulmonary artery pressure with 
continuous wave Doppler examination. The 
effect of pulmonary hypertension on the heart 
can be detected such as right atrial and right 
ventricle dilatation, right ventricle systolic 
function and left ventricle function.1,8 The 
presence of pulmonary hypertension signs in 
echocardiogram should be sought by experience 
echocardiographers, such as the alteration of LV 
geometry (LV-D shape), RV geometry (RV and 
RA dilatation with tricuspid valve regurgitation) 
and the Doppler measurement of pulmonary 
artery pressure (mean or systolic pressure).
Ventilation Perfusion Lung Scan (V/Q Lung 
Scan)
V/Q lung scan has negative predictive value 
of >98%, sensitivity of 96% and specificity 
of >90% to detect CTEPH.8 This value gives 
superiority of V/Q lung scan to rule-out CTEPH 
if the V/Q lung scan examination is normal. V/Q 
lung scan is an initial screening to diagnose 
CTEPH before proceeding to MDCTPA which 
have less sensitivity to detect CTEPH.8 Positive 
finding in V/Q scan suggestive CTEPH indicates 
the working diagnosis of CTEPH, however 
other condition may cause similar finding such 
as pulmonary venoocclusive disease.9 Easier 
interpretation and highly objectivity of V/Q 
lung scan makes it useful to screen CTEPH in 
the early phase of disease. V/Q lung scan has 
higher sensitivity to detect CTEPH in the more 
distal vessels.8 Furthermore, it only needs small 
amount of radiation, no intravenous contrast 
agent required and cost effective.10
The characteristic of CTEPH in V/Q lung scan 
is wedge-shaped perfusion deficit with normal 
ventilation pattern. Similar pattern is found in 
mediastinis fibrosa dan pulmonary venoocclusive 
disease.9 Other patterns may indicate other 
diseases, such as total loss of regional perfusion in 
lung carcinoma or vasculitis and small peripheral 
non-segmental perfusion defect  in pulmonary 
arterial hypertension. The distinguished pattern 
of CTEPH in V/Q lung scan prompts the 
confirmatory imaging modality with MDCTPA.8,11
Computed  Tomography  Pu lmonary 
Angiography
Multidetector CT pulmonary angiography 
(MDCTPA) is an imaging modality to confirm 
CTEPH after positive or non conclusive 
result of V/Q lung scan. The 3D multiplanar 
reconstruction can be accomplished to visualize 
the branches of pulmonary arteries. Resolution 
of imaging is precise (0.5 mm) in whole field 
therefore allowing quick acquisition and short 
breathholding time (5-10 seconds). MDCTPA 
with 64-detector has 97% sensitivity and 
95% specificity to detect lobar CTEPH and 
86% sensitivity and 93% specificity to detect 
segmental CTEPH. Higher 320-detector have 
greater sensitivity of 98% and specificity of 
97% in lobar CTEPH and sensitivity of 94% 
and spesificity of 95% in segmental CTEPH.12,13
The characteristic of CTEPH in MDCTPA 
is mosaic perfusion defect in lung parenchym, 
organised eccentric thrombus surrounding 
proximal pulmonary vessels, broncial arteries 
opened collateral, various size of lobar and 
segmental arteries, total or partial obstruction of 
pulmonary artery, dilatation of main pulmonary 
artery, right ventricular enlargement, filling 
defect, irregular vessel thickening, stenosis 
of pulmonary vessel and intraluminar webs 
and bands appearances.14 Furthermore, other 
examination can be performed with MDCTPA 
such as assessment of pulmonary and bronchial 
vessel anatomy to determine the operative 
procedure, evaluate perioperative risk, evaluate 
the mediastinum, lung and aorta and examine 
right ventricle structure.8
Right Heart Catheterisation and Pulmonary 
Angiography
Right heart catheterisation is performed to 
confirm the positive or inconclusive result on 
V/Q lung scan. The haemodynamic data can 
be evaluated with right heart catheterisation. 
The haemodynamic parameter is predictor 
of prognosis and risk for patients candidate 
to be performed pulmonary endarterectomy 
(PEA).14 The definitive diagnosis of CTEPH 
by right heart catheterisation is the finding of 
precapillary pulmonary hypertension (mPAP >25 
mmHg, PCWP <15 mmHg and PVR >2 Wood 
units) in patients with chronic thromboembolic 
obstruction or organised thrombus.8
Right heart catheterisation is accomplished 
concomitantly while performing selective 
pu lmonary  ang iography.  Righ t  hear t 
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catheterisation and selective pulmonary 
angiography is the gold standard to confirm 
CTEPH. Selective pulmonary angiography 
is performed to determine the extent and 
distribution of CTEPH, such that the eligibility of 
PEA can be selected. Typical angiographic defect 
in CTEPH is the evidence of organisation and 
recanalisation over thromboembolic material. 
These evidence are webs or bands appearance, 
intimal irregularity, sudden narrowing, proximal 
obstruction and pouch defect.5,15
CTEPH-THE TREATMENT
Guideline in Treatment
The guideline of CTEPH treatment from 
European Society of Cardiology  (2015) confirms 
three modalities, i.e. (1) surgery, (2) drugs and 
(3) intervention.1 The surgery is performed by 
pulmonary endarterectomy which has become 
main modality to cure CTEPH. The drugs used 
in CTEPH are the combination of oxygenation, 
diuretics and anticoagulant. Patients, whether 
treated by drugs or by surgery or intervention, 
must take lifelong anticoagulant to prevent 
the recurrence thromboembolism and the 
progression of thombus in pulmonary arteries. 
Warfarin is the anticoagulant most commonly 
prescribed in CTEPH and the international 
normalized ratio (INR) value is the indicator 
of acceptable anticoagulation state in the target 
range of 2 to 3.1 Riociguat is novel drug with 
proven efficacy to treat CTEPH. The intervention 
procedure is recommended for patients whom 
PEA can not be done or the risk of operation 
is high. Balloon pulmonary angioplasty is the 
intervention procedure currently develop in 
selected patients (Figure 4).1
Pulmonary Endarterectomy
Pulmonary endarterectomy (PEA) is 
procedure of choice to remove pulmonary 
artery obstruction in CTEPH. PEA procedure is 
delicate and complicated. A strict post operative 
management is mandatory. PEA procedure is 
curative for most patients. It is effective and has 
high success rate if performed with adequate 
patient selection, smooth operation technique and 
good post operative management. The mortality 
rate in the center with experience team is less 
than 5% (2.2%-4.7%).3
Several criteria to select patients candidate 
for PEA is important to increase success rate 
and reduce mortality rate. The criteria generally 
accepted are patients with WHO functional 
class II-IV, reachability of thrombus by surgery 
Figure 4. Treatment flow for CTEPH based on European Society Cardiology Guideline 20151
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in main, lobar and segmental pulmonary artery, 
proportional PVR value and right ventricle 
function.1,3 Other consideration is comorbity 
which may affect peri operative and post 
operative risk.
The PEA procedure involves the removal 
of all obstructive thromboembolic material 
from pulmonary artery including intimal and 
superficial medial layers. The goal is to reduce 
PVR, improve right ventricle function and 
increase ventilation/perfusion matching.16 
Based on Jamieson classification, PEA is more 
effective in lesion type 1 and 2. In lesion type 3, 
an experience center can perform the PEA with 
satisfactory result although persistent pulmonary 
hypertension may ensue.3
after being treated with prostanoid (intravenous 
epoprostenol, inhaled iloprost or subcutaneous 
treprostinil).17 BENEFit trial compared bosentan, 
a dual endothelin receptor antagonist, and 
placebo in 157 patients with in-operable or 
persistent/recurrent CTEPH for more than 16 
weeks. It showed that bosentan can not improve 
6 minute walking distance, WHO functional 
class and time to clinical worsening.18 Based 
on this trial, bosentan is not recommended to 
treat CTEPH although for idiopathic pulmonary 
artery hypertension it is proven beneficial. The 
trial with other endothelin receptor antagonist, 
macitentan, for CTEPH is on going.19
Riociguat is novel drug from the soluble 
guanilat cyclase (sGC) stimulator class. It has 
dual action, i.e. to increase sGC sensitivity from 
endogenous nitric oxide and elevate sGC activity 
independently from nitric oxide.20 The net effect 
of these properties are increased vasodilatation, 
antifibrotic activity, antiproliferative action and 
antiinflammation. The CHEST trial involving 
261 patients in operable CTEPH or patients 
with persistent/recurrent CTEPH after PEA 
randomised for riociguat and placebo. It showed 
more efficacy in riociguat arm as compared to 
placebo.20 In CHEST-2 trial the improvement 
is persisted in 1 year follow up and survival 
rate is 97.21 Based on this trial, riociguat 
is recommended in symptomatic patients, 
persisten/recurrent CTEPH after surgery or 
inoperable CTEPH.1,17
Balloon Pulmonary Angioplasty
Balloon pulmonary angioplasty (BPA) is 
relatively new procedure indicated in CTEPH 
patients who are not suitable for PEA or patients 
with residual or recurrent PH after PEA. It 
offers advantages over PEA, such as: (1) BPA 
can resolve the distal small lesions which 
cannot be reached with PEA and (2) BPA is a 
less-invasive procedure which does not need 
general anes¬thesia.22 Since BPA is originated 
from Japan, Japanese Circulation Society release 
the guideline for patients candidate for BPA, 
as follows: (1) patients unsuitable for PEA 
(lesion is not reachable, major comorbidities 
and persistent/residual/recurrent CTEPH after 
PEA), (2) patients with drugs treatment but fail 
to improve (WHO functional class ≥III after 




Clot in main vessel 
Clearly identified while opening 
pulmonary artery (20 % cases)
Operable
2
Only intimal thickening is seen 
Endarterectomy field seen early 
in main, lobar or segmental 




PEA limited in the branches of 
segmental and subsegmental 
vessels (10 % cases) 
Operable
4
Intrinsic small vessel disease
Secondary thrombus may 
occur due to stasis
Inoperable
Drugs Treatment
All patients with CTEPH must be given 
lifelong anticoagulant treatment with vitamin 
K antagonist, warfarin, in order to prevent in 
situ pulmonary artery thrombosis and recurrent 
venous thromboemboli.1 The target range for 
effective anticoagulant state is the INR value 
of 2 to 3.1 However, currently no randomised 
controlled trial for anticoagulant in CTEPH 
patients. Although PEA is curative treatment for 
CTEPH, around 35% patients still experience 
persisten or recurrent CTEPH after surgery. In 
these such population, targeted therapy with drugs 
is strongly indicated. Several non randomised 
small studies indicate the improvement of 
clinical and functional class of CTEPH patients 
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treatment, mPAP ≥30 mmHg or PVR ≥300 
persistent), (3) patients choice to have BPA 
after thorough informed consent about risk and 
benefit of BPA and PEA and (4) cases without 
serious complication, multiorgan failure or 
iodine allergy.23
Unlike PEA, BPA does not remove 
intraluminal thrombus or thrombotic material 
from pulmonary artery. BPA procedure makes 
medial layer dissection in the balloon inflation 
site and in situ thrombus partially disrupted from 
vessel walls.23 In facts BPA  procedure has similar 
technique as PEA, only in BPA the thrombi are 
not removed from the luminal blood vessel, but 
rather forced to one side so that luminal vessel 
become  larger.23 After the BPA, some parts of 
vessel walls becoming thin because of dissection, 
where the angioplasty than applied and produce 
expanded lumen diameter over time with little 
risk of restenosis (Figure 5).23
Figure 5. The procedure of BPA shows (A) the obstruction 
(arrow) in the pulmonary artery depicted in pulmonary 
angiography and (B) after BPA procedure the obstruction 
(arrow) is cleared and blood flow appears until peripheral 
artery. (Taken from: Ogawa and Matsubara, 201523 with 
permission).
The successful BPA is influenced by the 
extent and angiographic characteristics of the 
thromboembolic lesions, which can be classified 
as follows: ring-like stenosis lesion (type A), 
web lesion (type B), subtotal lesion (type C), 
total occlusion lesion (type D) and tortuous 
lesion (type E). The most favourable outcome 
is encountered in type A and B, whereas type D 
and E associate with lower success rate and high 
complication rate.24
CONCLUSION
The pathophysiology of CTEPH involves 
the derangement of pulmonary macrovascular 
and microvascular. The diagnosis of CTEPH 
requires high index of clinical suspicion, step-
by-step proper imaging modalities and adequate 
expertise to interpret the imaging. The treatment 
of CTEPH comprises surgery with PEA, drugs 
with anticoagulant and riociguat and intervention 
with BPA. Better diagnosis and correct patient 
selection to treatment strategy will improve 
survival of patients with CTEPH.
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